Reviva Pharmaceuticals I... (RVPH)
| Bid | 1.43 |
| Market Cap | 66.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -46M |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -1.33 |
| Forward PE | -2.19 |
| Analyst | Buy |
| Ask | 1.44 |
| Volume | 836,474 |
| Avg. Volume (20D) | 3,089,315 |
| Open | 1.39 |
| Previous Close | 1.43 |
| Day's Range | 1.33 - 1.48 |
| 52-Week Range | 0.60 - 4.28 |
| Beta | -0.12 |
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase...
Analyst Forecast
According to 6 analyst ratings, the average rating for RVPH stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 805.92% from the latest price.
2 months ago · seekingalpha.com
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is LowReviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announc...